---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-062451"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2026-05-15T20:00:58+00:00"
generated_at: "2026-05-15T20:03:38.102566+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Annovis Bio Q1 net loss $0.63/sh; AD Phase 3 85% enrolled; NDA planned early 2027

## Summary
- Net loss per share $0.63 (vs $0.32 in Q1 2025); R&D spend $16.7M (up from $5.0M).
- Cash $14.2M at Mar 31, 2026; $10M April offering not included; 28.5M shares outstanding.
- Phase 3 AD trial 85% enrolled, full enrollment on track summer 2026; DSMB safety recommendation positive.
- PD OLE study 40% enrolled; NDA for buntanetap symptomatic AD treatment expected early 2027.

## SEC filing metadata
- accession: 0001104659-26-062451
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2026-05-15T20:00:58+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465926062451/0001104659-26-062451-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465926062451/tm2614822d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-062451
- JSON: https://secwatch.observer/filing/0001104659-26-062451.json
- Plain text: https://secwatch.observer/filing/0001104659-26-062451.txt

## Key facts
- Earnings Releases
  Annovis Bio, Inc. reported first quarter ended March 31, 2026 results: EPS $0.63 basic and diluted net loss per common share.
  - Period: first quarter ended March 31, 2026
  - EPS: $0.63 basic and diluted net loss per common share
  - Result: reported results
  source text: Annovis reported a $0.63 basic and diluted net loss per common share for the three months ended March 31, 2026, compared to a $0.32 basic and diluted net loss per common share for the three months ended March 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1477845/000110465926062451/0001104659-26-062451-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.